Objective To compare the clinical efficacy of two methods in the prevention and treatment of tendon adhesion after flexor tendon suture. Methods Sixty patients of flexor tendon rupture treated in our rehabilitation center from June 2017 to June 2020 were selected and divided into treatment group (emodin ultrasound treatment) and control group (ultrasound guided therapy ). The clinical efficacy before and after treatment was evaluated by visual analogue scale (VAS), clinical tendon repair efficacy standard and finger flexion strength of patients. Results All the 60 patients were followed up for 2~12 weeks (average 7 weeks), and incisions in all patients healed in the first stage. VAS scores of fingers were significantly decreased after treatment compared with the control group (only ultrasound guided therapy), with statistical significance (P<0.05). After 7 weeks, the TAM scores of hand function in the two groups were compared. In the treatment group, 67% (20/30) of treatment were markedly effective, 30% (9/30) were effective, 10% (1/30) were ineffective, the total effective rate was 97%. In the control group, 23% (7/30) and 60% (18/30) of treatment were effective, 17% (5/30) were ineffective, and the total effective rate was 83%. In particular, the flexor strength of the treatment group was significantly higher than that of the control group, and the difference was statistically significant. Conclusion Ultrasound guided therapy combined with emodin in the prevention and treatment of flexor tendon adhesion has reliable clinical efficacy and less adverse reactions, which is worthy of clinical application.

Objective: To investigate the clinical efficacy and safety of Apatinib Mesylate in the treatment of advanced gastric cancer patients who failed second-line chemotherapy. Methods: 80 postoperative patients with advanced gastric cancer who failed second-line chemotherapy were randomly divided into observation group and control group, with 40 cases in each group. The patients in control group were treated with conventional chemotherapy, 2 weeks as a course of treatment and all the patients were treated for 4 courses. The patients in observation group were treated with conventional chemotherapy combined Apatinib Mesylate, 1 week of Apatinib Mesylate was a course of treatment and all the patients were treated 4 courses. After treatment, RECIS solid tumor efficacy evaluation criteria was used to evaluate the clinical efficacy, and adverse reactions were also observed. Results: The total effective rate and disease control rate of patients in the observation group were 50.0% and 90.0% respectively, which were all obviously higher than control group (P<0.05).The incidence of hypertension, vomiting, diarrhea, rash, hand-foot syndrome, stomatitis of patients in observation group were all obviously lower than control group (P<0.05). Conclusions: Apatinib Mesylate combined conventional chemotherapy can obviously improve the curative effects of advanced gastric cancer patients who failed second-line chemotherapy, and the incidence of adverse reactions are lower, so it is worthy of clinical promotion.